|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
29 June 2015 |
|
Main ID: |
NCT02478073 |
|
Date of registration:
|
15/06/2015 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Piperacillin Pharmacokinetics in ICU Patients
|
|
Scientific title:
|
Piperacillin Pharmacokinetics in Intensive Care Unit Patients Following Standard Treatment With Intermittent and Continuous Infusion |
|
Date of first enrolment:
|
June 2015 |
|
Target sample size:
|
50 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT02478073 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Case-Only, Time Perspective: Prospective
|
|
Phase:
|
N/A
|
|
|
Countries of recruitment
|
|
Denmark
| | | | | | | |
|
Contacts
|
|
Name:
|
Kristina Öbrink-Hansen, MD |
|
Address:
|
|
|
Telephone:
|
+45 78452845 |
|
Email:
|
krisoebr@rm.dk |
|
Affiliation:
|
|
|
|
Name:
|
Jakob Gjedsted, MD, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Aarhus University Hospital, Department of Anesthesia and Intensive Care Medicine |
|
|
Name:
|
Jakob Gjedsted, MD, PhD |
|
Address:
|
|
|
Telephone:
|
+45 78451030 |
|
Email:
|
jakob.gjedsted@auh.rm.dk |
|
Affiliation:
|
|
|
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Sepsis or septic shock
- Treatment with piperacillin/tazobactam
Exclusion Criteria:
- Age under 18 years
- Renal replacement therapy
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Sepsis
|
|
Septic Shock
|
|
Primary Outcome(s)
|
|
Blood-plasma concentration of Piperacillin
[Time Frame: A blood-test will be drawn 1-3 times weekly. Participants will be followed for the duration of piperacillin/tazobactam treatment, an expected average time of two weeks.]
|
|
Secondary Outcome(s)
|
|
Percentage of time above the minimal inhibitory concentration (T>MIC)
[Time Frame: A blood-test will be drawn 1-3 times weekly. Participants will be followed for the duration of piperacillin/tazobactam treatment, an expected average time of two weeks.]
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|